Update on reslizumab for eosinophilic asthma

Expert Opinion on Biological Therapy

Volumn 15, Issue 10, 2015, Pages 1531-1539

  Cardet, Juan Carlos ^a,b,c   Israel, Elliot ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Allergy Associates   (United States)

Author keywords

anti IL 5 therapy; asthma; eosinophil; eosinophilic inflammation; IL 5; monoclonal antibody; reslizumab

Indexed keywords

INTERLEUKIN 5 ANTIBODY; RESLIZUMAB; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ARTICLE; ASTHMA; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG SAFETY; EOSINOPHIL; EOSINOPHILIA; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; CLINICAL TRIAL (TOPIC); CYTOLOGY; FACTUAL DATABASE; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EOSINOPHILS; HUMANS; INTERLEUKIN-5; SIGNAL TRANSDUCTION;

EID: 84942051066     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1090972     Document Type: Article

References (74)

1. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol 2011;127(1):145-52
2. Moorman JE, Zahran H, Truman BI, Molla MT. Current asthma prevalence-United States, 2006-2008. MMWR Surveill Summ 2011;60(Suppl):84-6
3. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343-73
4. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? the gaining optimal asthma control study. Am J Respir Crit Care Med 2004;170(8):836-44
5. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180(5):388-95
6. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185(6):612-19
7. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010;181(4):315-23
8. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127(2):355-60
9. Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ 2014;349:g5517
10. Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med 2014;20(1):87-94
11. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol 2015;135(2):299-310
12. Nair P. What is an "eosinophilic phenotype" of asthma? J Allergy Clin Immunol 2013;132(1):81-3
13. Kita HAB, Bruce S. Biology of eosinophils. In: Adkinson NF, editor. Middleton's allergy: principles and practice. 8th edition. Saunders, Elsevier, Inc, Philadelphia, Pennsylvania; 2014. p. 265-79
14. Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ J 2014;7(1):32
15. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 2015;3(2):167-74
16. Garcia G, Taille C, Laveneziana P, et al. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev 2013;22(129):251-7
17. McCallister JW. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy? Am J Respir Crit Care Med 2011;184(10):1096-7
18. Lim HF, Nair P. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Rev Respir Med 2015;9(2):135-42
19. Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics 2013;7:7-11
20. Ellis AG. The pathological anatomy of bronchial asthma. Am J Med Sci 1908;136:407-29
21. Houston JC, De Navasquez S, Trounce JR. A clinical and pathological study of fatal cases of status asthmaticus. Thorax 1953;8(3):207-13
22. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med 1975;292(22):1152-5
23. Taylor KJ, Luksza AR. Peripheral blood eosinophil counts and bronchial responsiveness. Thorax 1987;42(6):452-6
24. Gundel RH, Gerritsen ME, Gleich GJ, Wegner CD. Repeated antigen inhalation results in a prolonged airway eosinophilia and airway hyperresponsiveness in primates. J Appl Physiol (1985) 1990;68(2):779-86
25. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323(15):1033-9
26. Davis WB, Fells GA, Sun XH, et al. Eosinophil-mediated injury to lung parenchymal cells and interstitial matrix. A possible role for eosinophils in chronic inflammatory disorders of the lower respiratory tract. J Clin Invest 1984;74(1):269-78
27. Gleich GJ, Loegering DA, Adolphson CR. Eosinophils and bronchial inflammation. Chest 1985;87(1 Suppl):10S-3S
28. Yasukawa A, Hosoki K, Toda M, et al. Eosinophils promote epithelial to mesenchymal transition of bronchial epithelial cells. PLoS One 2013;8(5):e64281
29. Gleich GJ. Mechanisms of eosinophilassociated inflammation. J Allergy Clin Immunol 2000;105(4):651-63
30. Frigas E, Loegering DA, Solley GO, et al. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc 1981;56(6):345-53
31. Flavahan NA, Slifman NR, Gleich GJ, Vanhoutte PM. Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis 1988;138(3):685-8
32. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991;87(4):1470-3
33. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360(9347):1715-21
34. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27(3):483-94
35. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989;73(6):1504-12
36. Steinke JW, Rosenwasser LJ, Borish L. Cytokines in allergic inflammation. In: Adkinson NF, editor. Middleton's allergy: principles and practice. 8th edition. Elsevier, Philadelphia, Pennsylvania; 2014. p. 65-82
37. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013;19(8):977-9
38. Lalani T, Simmons RK, Ahmed AR. Biology of IL-5 in health and disease. Ann Allergy Asthma Immunol 1999;82(4):317-32. quiz 32-3
39. Foster PS, Hogan SP, Ramsay AJ, et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996;183(1):195-201
40. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991;87(5):1541-6
41. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326(5):298-304
42. Humbert M, Corrigan CJ, Kimmitt P, et al. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997;156(3 Pt 1):704-8
43. Corrigan CJ, Haczku A, Gemou-Engesaeth V, et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis 1993;147(3):540-7
44. Shi H, Qin S, Huang G, et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol 1997;16(3):220-4
45. Johansson MW, Mosher DF. Integrin activation States and eosinophil recruitment in asthma. Front Pharmacol 2013;4:33
46. Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 1999;49(9):779-90
47. Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 1999;11(12):1935-44
48. Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108(2):250-7
49. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6(5):343-57
50. Ghazi A, Trikha A, Calhoun WJ. Benralizumab-a humanized mAb to IL-5Ralpha with enhanced antibodydependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma. Expert Opin Biol Ther 2012;12(1):113-18
51. Denburg JA, Silver JE, Abrams JS. Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood 1991;77(7):1462-8
52. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167(12):1655-9
53. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167(2):199-204
54. Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-8
55. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985-93
56. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-84
57. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184(10):1125-32
58. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118(5):1133-41
59. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2(11):879-90
60. Clinicaltrials. gov identifier NCT01508936. 2015. Available from: https:// clinicaltrials. gov/show/NCT01508936
61. Clinicaltrials. gov identifier NCT01270464. 2015. Available from: http:// ClinicalTrials. gov/show/NCT01270464 [Last accessed 04 June 2015]
62. Corren JEA. A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. Eur Respir J 2014;44(Suppl 58):4673
63. Bjermer L. A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Respir J 2014;44:Suppl 58
64. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3(5):355-66
65. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371(13):1198-207
66. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371(13):1189-97
67. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651-9
68. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008;121(6):1473-83. 83e1-4
69. Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004;114(6):1449-55
70. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month followup analysis. J Allergy Clin Immunol 2014;133(3):921-3
71. Takeda K, Shiraishi Y, Ashino S, et al. Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge. J Allergy Clin Immunol 2015;135(2):451-60
72. Nair P. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma. N Engl J Med 2014;371(13):1249-51
73. Rothenberg ME, Hogan SP. The eosinophil. Ann Rev Immunol 2006;24:147-74
74. HE-stained eosinophil. Available from: https://virtualmedic. wordpress. com/2011/02/17/histology-of-eosinophilhistology/ [Last accessed 24 April 2015]